Pherecydes Pharma

8th ASM Biodefense & Emerging Diseases Conference

For the third time in less than 2 years Pherecydes Pharma is presenting at a biofense conferences, in the USA.

Hôpital Robert Debré collaboration

On February 7th, 2010, Robert Debré Hospital (Paris-France) and Pherecydes Pharma signed an agreement to select bacteriophage variants for eradicating different Escherichia coli strains.

Read all news

WELCOME to Pherecydes Pharma

Pherecydes Pharma is developing new tools to rapidly detect and/or kill a large range of bio threats, including multiresistant, emergent or previously uncharacterized bacteria, to treat people and/or environments.
Pherecydes Pharma owns proprietary methods for accelerated targeted protein evolution, to engineer phages into targetable nano devices.

Bacterial threats applications

Natural biocide to control human or animal bacterial infections
Diagnostic for industrial and medical applications
Biosecurity and biodefence to combat bioterrorism
Disinfection of surfaces, food products…

Bio nano applications

Pherecydes Pharma is a phage and nanotechnology R&D start up Company that is developing new patented approaches in bio nano engineering: